Status:
COMPLETED
COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine
Lead Sponsor:
Sciensano
Collaborating Sponsors:
Mensura EDPB
Institute of Tropical Medicine, Belgium
Conditions:
Covid19
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
This is a randomized phase IV dose-optimization study evaluating the safety and immunogenicity of two doses of COVID-19 mRNA vaccines being authorized in the European Union since December 2020: Vaccin...
Detailed Description
Background: Data from the dose-escalating phase 1 trials from the COVID-19 mRNA vaccines being authorized in the European Union since December 2020, BNT162b2 (Comirnaty®; Pfizer- BioNTech) indicate th...
Eligibility Criteria
Inclusion
- Working at Mensura EDPB, not yet vaccinated for COVID19 -
Exclusion
- \-
Key Trial Info
Start Date :
May 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT04852861
Start Date
May 10 2021
End Date
September 30 2022
Last Update
March 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mensura EDPB
Antwerp, Belgium, 2000